TY - JOUR
T1 - Biomarkers of treatment outcome in schizophrenia
T2 - Defining a benchmark for clinical significance
AU - Levine, Stephen Z.
AU - Rabinowitz, Jonathan
AU - Uher, Rudolf
AU - Kapur, Shitij
N1 - Funding Information:
Dr. Uher is supported by the Canada Research Chairs program, the Canadian Institutes of Health Research and the Nova Scotia Health Research Foundation. Dr. Levine has received research support, and/or consultancy fees and/or travel support from Shire, F. Hoffmann-LaRoche, and Eli Lilly. Dr. Rabinowitz has served as a consultant to Janssen (J&J), Eli Lilly, Pfizer, BiolineRx, Roche and Amgen, and is on scientific advisory board at MedAvante. Dr. Kapur has received recent grant support from Lundbeck and Roche and has served as a one-off consultant and/or speaker for Otsuka and Takeda and served on the Scientific Advisory Boards for Acadia, Lundbeck and Roche
Funding Information:
Dr. Kapur's involvement is supported by an MRC UK Award, STRATA and by the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King’s College London .
Publisher Copyright:
© 2015 Elsevier B.V. and ECNP.
PY - 2015/10
Y1 - 2015/10
UR - http://www.scopus.com/inward/record.url?scp=84943363681&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84943363681&partnerID=8YFLogxK
U2 - 10.1016/j.euroneuro.2015.06.008
DO - 10.1016/j.euroneuro.2015.06.008
M3 - Article
C2 - 26145487
AN - SCOPUS:84943363681
SN - 0924-977X
VL - 25
SP - 1578
EP - 1585
JO - European Neuropsychopharmacology
JF - European Neuropsychopharmacology
IS - 10
ER -
